Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics
Biocon Biologics’ subsidiary Biocon in Malaysia has been awarded a three-year contract, valued at $90 million (MYR 375 million), for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.
Biocon, a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing (DMktg), a subsidiary of Duopharma Biotech, a leading pharmaceutical and biotech company in Malaysia.
Biocon Biologics’ Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.
Susheel Umesh, Chief Commercial Officer, Emerging Markets, Biocon Biologics, said, “We are pleased to renew our commitment to provide affordable access to our recombinant human insulin for people with diabetes in Malaysia through this new government contract. This will enable us to serve over 400,000 people with diabetes using recombinant human insulin, helping the government in its journey towards equitable access to diabetes care.”
The rh-Insulin formulations, Insugen-R, Insugen-N and Insugen-30/70, are manufactured at Biocon’s Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.
Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor, is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive US FDA and EMA approval. More recently, Biocon’s biosimilar insulin Glargine made in Malaysia has received a historic US FDA approval as the ‘first interchangeable biosimilar’.
Through its scientifically validated, high-quality human insulin and analogue products manufactured in Malaysia, Biocon Biologics is providing affordable access to these life-saving therapies to patients in many developed markets like the US, the EU, Australia, as well as many emerging market countries in the Middle East and Latin America.
